In an Expert View piece, Rosanne Kay, partner at international law firm Reed Smith, considers when to escalate matters to an internal investigation, and how best to carry them out.
It is relatively unavoidable for many healthcare companies that they will devote resources and time to carrying out internal investigations, whether into allegations that have arisen through whistleblowers or their own monitoring. What are some of the best ways to ensure that such investigations are as effective as possible?
Before beginning
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze